OakChart

Innate Pharma ADR

IPHAHealthcare·Biotechnology·France·Micro·NASD·Nov 10 • 3:59 PM ET

1.540.00 (0.00%)
2026-11-11 14:44 CET
Market cap
172.01 USD m
Revenue, TTM
4.94 USD m
Net income, TTM
-55.35 USD m
Free cash flow, TTM
-51.79 USD m
EPS diluted, TTM
-0.59
P/E
-
Compare

Price

IPHA against its 20, 50 and 200-day averages
2050200beat
1.502.002.503.4M6.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IPHAclose 1.5420-day 1.4750-day 1.66200-day 1.701.54

43.2% under 2.71 on 13 Aug 2026. Last 15 sessions, 21.2% high to low

Profile

IPHA
52-week range, 24% of the way up
1.172.71

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Herve Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournie, and Francois Romagne on September 23, 1999 and is headquartered in Marseille, France.

Employees163
IPOOct 17, 2019
Beta0.75
ATR, 14d0.09
Rel volume0.00
Inst own0.17%

Snapshot

6 groups

Valuation

Index-
Market Cap172.01M
Enterprise Value182.65M
Income-55.35M
Sales4.94M
Book/sh-0.49
Cash/sh0.11
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees163
IPOOct 17, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S34.82
P/B-
P/C13.80
P/FCF-
EV/EBITDA-
EV/Sales36.97
Quick Ratio0.60
Current Ratio0.60
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.59
EPS next Y-0.21
EPS next Q-0.11
EPS this Y90.22%
EPS next Y-232.89%
EPS next 5Y-
EPS past 3/5Y6.86% 7.69%
Sales past 3/5Y-60.77% -45.26%
EPS Y/Y TTM1.17%
Sales Y/Y TTM-24.21%
EPS Q/Q8.99%
Sales Q/Q99.10%
EarningsNov 05 BMO
EPS/Sales Surpr.18.13% 2.38%

Ownership

Insider Own-
Insider Trans-
Inst Own0.17%
Inst Trans4.26%
ROA-74.40%
ROE-
ROIC-
Gross Margin-
Oper. Margin-1257.04%
Profit Margin-1121.55%
SMA204.71%
SMA50-7.03%
SMA200-9.55%
Trades-

Technical

Shs Outstand93.90M
Shs Float-
Short Float-
Short Ratio2.28
Short Interest0.12M
52W High2.71 -43.18%
52W Low1.17 31.62%
Volatility5.45% 4.92%
ATR (14)0.09
RSI (14)51.45
Beta0.75
Rel Volume0.00
Avg Volume54.03K
Volume0

Performance

Perf Week15.78%
Perf Month4.05%
Perf Quarter-37.66%
Perf Half Y13.23%
Perf YTD-12.01%
Perf Year-33.05%
Perf 3Y-35.03%
Perf 5Y-71.54%
Perf 10Y-
Recom1.00
Target Price6.87
Prev Close1.54
Price1.54
Change %0.00%

Analyst ratings

latest 8 of 8
DateActionAnalystRating changeTargetImplied
Aug 11, 2026UpgradeLLeerink PartnersMarket Perform → Outperform$4+159.8%
Mar 12, 2026ResumedBBTIG ResearchBuy$8+419.5%
Sep 18, 2025DowngradeLLeerink PartnersOutperform → Market Perform
Sep 18, 2025DowngradeHH.C. WainwrightBuy → Neutral
Jul 28, 2025InitiatedBBTIG ResearchBuy$8+419.5%
Sep 03, 2021UpgradeSSVB LeerinkMkt Perform → Outperform$7+354.6%
Dec 15, 2020DowngradeSSVB LeerinkOutperform → Mkt Perform$7 → $5+224.7%
Nov 24, 2020InitiatedGGoldmanNeutral$4.75+208.5%

Peers

Mkt cap
TickerCompanyMkt cap
ALXOAlx Oncology Holdings Inc154.87M
BCYCBicycle Therapeutics Plc ADR186.57M
AGENAgenus Inc312.65M
NKTXNkarta Inc105.20M
XNCRXencor Inc2.96B
CRVSCorvus Pharmaceuticals Inc959.10M
CUECue Biopharma Inc136.28M
CMPXCompass Therapeutics Inc156.67M
CTORCitius Oncology Inc52.32M
ZYMEZymeworks BC Inc2.22B

News

latest 14 of 103
  • Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026 (Business Wire)
  • Innate Pharma Reports Third Quarter 2026 Business and Financial Update (Business Wire)
  • Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027 (Business Wire)
  • Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference (Business Wire)
  • Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update (Business Wire) +8.08%
  • Loading…
  • Innate Pharma Reports First Half 2026 Business Update and Financial Results (Business Wire)
  • Sobi and Innate announce partnership is now effective following completion of closing conditions (PR Newswire) +8.06%
  • Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions (Business Wire)
  • Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update (Business Wire)
  • Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (Business Wire)
  • Innate Pharma SA (IPHA) (Q2 2026) Earnings Call Highlights: Strategic Partnerships and Pipeline ... (GuruFocus.com)
  • Innate Pharma Announces Conference Call and Webcast (Business Wire) -14.00%
  • Sobi licenses Innates CTCL drug for up to $580m as it heads to Phase III (Pharmaceutical Technology) +28.32%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026S12026-09-17-0.241-0.295-0.2396.506.352
2025S22026-03-26-0.346-0.349-0.3464.795.701
2025S12025-09-17-0.296-0.329-0.2685.7614.081
2024S22025-03-27-0.346-0.267-0.3298.6718.242
2024S12024-09-12-0.342-0.300-0.33113.6313.301
2023S22024-03-21-0.130-0.436-0.12423.2418.153
2023S12023-09-140.0210.0860.02242.8768.551
2022S22023-03-23-0.893--0.81413.17-3
2022S12022-09-150.0800.3800.08445.5784.341
2021S22022-06-08-0.378--0.42517.50-2
2021S12021-09-15-0.355-0.304-0.36218.5430.632
2020S22021-06-01-0.811--0.80240.19--
2020S12020-09-08-0.153--0.14443.33-2
2019S22020-05-30-0.512--0.57429.62-1
2019Q32019-11-130.045-0.088-30.5024.381
2019S12019-09-130.222-0.9860.22965.5742.991

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.340-0.082-0.34797.35107.67
2020FY-0.966-0.519-0.92484.0193.28
2021FY-0.627-0.600-0.78527.1951.74
2022FY-0.795-0.322-0.76762.8172.80
2023FY-0.098-0.611-0.10266.9559.77
2024FY-0.659-0.375-0.66021.7341.70
2025FY-0.635-0.640-0.63510.3917.29
2026FY--0.062--58.19
2027FY--0.207--71.43
2028FY-0.485--127.59
2029FY--0.027--68.54
2030FY-0.608--167.74

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026S2S2026-11-061012.792.792.79
2026S2S2026-09-181012.912.912.91
2026S2S2026-09-171013.473.473.47
2026S2S2026-08-271013.473.473.47
2026S2S2026-08-1021170.003.47136.53
2026S2S2026-08-0720130.303.4757.14
2026S2S2026-07-2720030.333.5157.14
2026S2S2026-07-0422030.333.5157.14
2026S2S2026-05-1332021.953.5157.14
2026S2S2026-04-0630121.663.4656.32
2026S2S2026-03-2620030.765.1956.32
2026S2S2026-01-111003.613.613.61
2026S2S2026-01-091013.613.613.61
2026S2S2025-11-2120132.013.6160.40

Estimate history

EPS, annual-1.0040.061-0.347-0.924-0.785-0.767-0.102-0.66-0.62
Period201720182019202020212022202320242025
EPS, quarterly
Period
Sales, annual36.80694.25377.19964.01514.31652.10756.11113.6533.145
Period201720182019202020212022202320242025
Sales, quarterly
Period
Shares, annual57.58263.90778.54778.96879.54380.19380.84283.81293.701
Period201720182019202020212022202320242025
Shares, quarterly
Period

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue4.943.1513.6556.1152.1114.3264.0277.2094.25
Selling, General and Administrative Excl. Other65.4766.3275.4374.8373.3483.0268.2298.7495.36
Research and Development46.1746.1155.0956.3651.3354.5347.8970.9974.85
Other Operating Expense0.000.000.000.000.000.000.000.00-
Operating Income-62.04-64.73-63.93-24.23-25.88-74.11-14.90-40.04-9.84
Interest Expense0.440.500.610.690.300.370.390.230.75
Unusual Expense-0.442.42-2.14-1.7844.81-1.280.634.655.96
Net Income Before Taxes-61.84-62.50-61.61-18.70-69.37-68.64-16.47-42.08-13.38
Income Taxes-6.49-7.00-8.10-10.52-8.44-14.88-15.52-18.85-16.98
Consolidated Net Income-55.35-55.50-53.51-8.18-60.93-53.75-0.95-23.233.60
Net Income From Continuing Operations-55.35-55.50-53.51-8.18-60.93-53.75-0.95-23.233.60
Net Income-55.35-55.50-53.51-8.18-61.06-62.42-72.94-23.233.60
EPS (Recurring)-0.59-0.60-0.68-0.12-0.37-0.80-0.92-0.300.13
EPS (Basic, Before Extraordinaries)-0.59-0.62-0.66-0.10-0.77-0.78-0.92-0.350.06
EPS (Diluted)-0.59-0.62-0.66-0.10-0.77-0.78-0.92-0.350.06
EBITDA-60.53-63.17-61.78-18.72-21.23-68.71-4.20-21.54-1.10
Non-Operating Income (Expense)0.205.140.784.431.624.56-0.552.843.17
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.822.174.274.602.752.272.032.952.13
Price To Earnings Ratio--------10.42
Price To Sales Ratio34.9849.8510.924.015.7025.345.045.58-
Operating Margin-1,257.04-2,058.02-468.22-43.18-49.68-517.64-23.28-51.87-10.44
Net Margin-1,121.55-1,764.51-391.94-14.59-117.19-436.01-113.94-30.103.82
Shares Outstanding93.9093.7083.8180.8480.1979.5478.9778.5563.91
Market Capitalization172.01172.01152.32225.75299.19360.52322.95505.49504.70

Income statement, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S22023S12022S2
Total Revenue3.631.301.834.698.9617.9138.198.42
Selling, General and Administrative Excl. Other28.0737.4032.3134.8540.5534.9039.9335.20
Research and Development19.4726.7122.1324.3330.7325.6630.7025.50
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-25.15-36.89-31.25-31.08-32.82-18.56-5.68-29.19
Interest Expense0.200.250.250.290.320.340.350.10
Unusual Expense-0.10-0.33-0.51-0.55-1.59-0.65-1.1340.92
Net Income Before Taxes-25.86-35.98-26.79-30.47-31.14-15.32-3.39-69.03
Income Taxes-2.97-3.52-3.48-3.72-4.38-5.27-5.25-3.82
Consolidated Net Income-22.89-32.46-23.31-26.75-26.77-10.051.86-65.22
Net Income From Continuing Operations-22.89-32.46-23.31-26.75-26.77-10.051.86-65.22
Net Income-22.89-32.46-23.31-26.75-26.77-10.051.86-65.27
EPS (Recurring)-0.24-0.35-0.27-0.33-0.34-0.130.01-0.46
EPS (Basic, Before Extraordinaries)-0.24-0.35-0.27-0.33-0.33-0.120.02-0.81
EPS (Diluted)-0.24-0.35-0.27-0.33-0.33-0.120.02-0.81
EBITDA-24.44-36.10-30.48-30.17-31.58-16.99-1.74-26.78
Non-Operating Income (Expense)-0.620.824.200.350.412.931.511.18
Stock Option Compensation Expense0.940.891.272.421.843.091.510.02
Price To Sales Ratio34.9852.4524.2310.955.844.035.535.59
Operating Margin-692.10-2,834.23-1,712.51-663.22-366.15-103.62-14.86-346.66
Net Margin-629.95-2,494.00-1,277.32-570.73-298.61-56.104.86-775.14
Shares Outstanding93.9093.7092.1683.8180.9580.8480.5080.19
Market Capitalization172.01161.31167.27152.32157.04225.75247.33299.19

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments40.3083.64102.13108.31136.28185.54245.68191.51139.42
Short Term Receivables8.941.7051.3633.1115.3216.9714.7567.8318.11
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets5.623.4510.027.825.629.726.29106.067.60
Total Current Assets54.8688.79163.50149.23157.22212.23266.71365.40165.14
Net Property, Plant & Equipment5.125.326.989.1211.5714.3113.1011.6812.88
Total Investments and Advances12.2810.6510.8237.4845.3547.6441.5437.8870.15
Intangible Assets0.000.000.461.6650.2656.64108.8596.6355.47
Deferred Tax Assets--9.959.145.728.671.441.78-
Other Assets1.4110.2511.7515.2134.0836.6718.892.432.59
Total Assets73.66115.00193.52221.84304.20376.15450.53515.81306.23
Short Term Debt Incl. Current Port. of LT Debt10.349.029.872.2434.972.622.391.541.16
Accounts Payable8.788.209.4614.5716.7525.3631.3647.6423.98
Other Current Liabilities23.9316.9324.4627.3039.1327.67103.00175.7263.61
Total Current Liabilities43.0434.1543.7844.1290.8555.66136.75224.9088.75
Long Term Debt16.1723.0834.2042.8515.3620.7318.633.634.53
Provision for Risks Charges2.653.113.362.933.675.384.384.274.36
Deferred Tax Liabilities--9.959.145.728.671.441.78-
Other Liabilities37.2945.5154.8465.0166.4294.8645.2890.04105.37
Total Liabilities99.15105.85136.19164.05182.02185.30206.48324.63203.02
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-25.499.1557.3357.79122.18190.84244.05191.18103.22
Total Shareholders Equity-25.499.1557.3357.79122.18190.84244.05191.18103.22
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-25.499.1557.3357.79122.18190.84244.05191.18103.22
Total Liabilities & Stockholders Equity73.66115.00193.52221.84304.20376.15450.53515.81306.23
Book Value Per Share-0.270.110.710.721.542.423.112.991.79
Tangible Book Value Per Share-0.270.110.700.700.901.701.721.480.83
Full-Time Employees163181179210215237235195188
Price to Book Ratio-3.124.833.572.452.971.692.071.99-
Return on Assets-58.84-33.61-3.94-23.16-15.80-0.23-4.810.88-18.09
Return on Equity--160.99-14.22-67.71-34.34-0.43-10.682.44-56.23
Return on Invested Capital--166.06-8.94-60.68-45.38-34.47-8.851.85-50.65
Quick Ratio1.272.603.733.381.733.811.951.621.86
Current Ratio1.272.603.733.381.733.811.951.621.86

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-56.93-55.50-53.51-8.18-61.06-62.42-72.94-23.233.60
Depreciation1.551.562.155.514.655.4010.7018.508.73
Other Funds (Non Cash)2.136.841.542.1749.42-0.3360.03-0.016.44
Funds from Operations-53.25-47.10-49.82-0.50-6.99-57.35-2.21-4.7418.77
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital1.66-12.0042.36-34.69-13.14-11.68-56.0945.04-55.56
Income Taxes Payable--0.43-0.53------
Cash from Operating Activities-51.58-59.10-7.46-35.20-20.13-69.03-58.3140.30-36.79
Capital Expenditures-0.20-0.16-0.42-2.54-1.18-1.57-12.93-73.21-1.69
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.160.000.010.010.000.03
Purchase or Sale of Investments2.887.9410.3724.613.150.00-3.422.2428.57
Purchase of Investments0.000.000.000.000.000.00-3.420.000.00
Sale Or Maturity of Investments2.887.9410.3724.613.150.000.002.2428.57
Other Uses0.120.000.000.000.000.000.000.000.00
Other Sources0.010.010.000.070.000.050.000.000.03
Cash from Investing Activities2.807.799.9522.301.97-1.52-16.34-70.9726.94
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock1.1616.913.170.430.210.590.0673.9373.93
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock1.1616.913.170.430.210.590.0673.9373.93
Proceedsfrom Stock Options1.1616.913.170.430.210.590.0673.9373.93
Issuance or Reduction of Debt, Net-13.15-10.06-9.67-2.55-2.1331.48-1.0113.34-1.59
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities-7.126.85-6.50-2.13-1.9232.07-0.9587.2772.35
Exchange Rate Effect-0.141.23-0.550.30-0.45-0.570.250.00-0.03
Net Change in Cash-56.04-43.23-4.55-14.72-20.53-39.05-75.3556.6062.46
Free Cash Flow-51.79-59.26-7.88-35.58-20.69-70.13-59.3438.88-37.82
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow-------11.08-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Cash & Short Term Investments12.4640.3070.4683.6498.39102.13
Short Term Receivables5.248.941.421.7014.8251.35
Inventories0.000.000.000.000.000.00
Other Current Assets4.715.624.403.456.4010.02
Total Current Assets22.4154.8676.2788.79119.60163.50
Net Property, Plant & Equipment4.175.125.825.326.166.98
Total Investments and Advances11.9812.2812.2010.6511.0910.82
Intangible Assets0.000.000.000.000.130.46
Deferred Tax Assets----9.789.95
Other Assets1.151.4114.8110.2515.6111.75
Total Assets39.7073.66109.09115.00162.37203.47
Short Term Debt Incl. Current Port. of LT Debt12.3410.3410.499.029.579.87
Accounts Payable6.218.785.348.209.389.46
Other Current Liabilities19.0223.9318.7116.9322.0224.46
Total Current Liabilities37.5643.0434.5434.1540.9743.79
Long Term Debt10.7716.1721.2423.0828.4834.20
Deferred Tax Liabilities----9.789.95
Other Liabilities35.0037.2943.6045.5149.3254.84
Total Liabilities86.0299.15103.06105.85131.51146.14
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-46.31-25.496.049.1530.8657.33
Total Shareholders Equity-46.31-25.496.049.1530.8657.33
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-46.31-25.496.049.1530.8657.33
Total Liabilities & Stockholders Equity39.7073.66109.09115.00162.37203.47
Book Value Per Share-0.49-0.270.070.110.380.71
Tangible Book Value Per Share-0.49-0.270.070.110.380.70
Price to Book Ratio-3.1226.7116.634.832.743.57
Return on Assets-74.40-59.12-36.88-33.61-19.40-3.85
Return on Equity---271.32-160.99-78.33-14.23
Return on Invested Capital---85.46-83.00-45.11-10.98
Quick Ratio0.601.272.212.602.923.73
Current Ratio0.601.272.212.602.923.73

Cash flow, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Net Income-22.89-34.04-23.31-26.79-26.77-10.05
Depreciation0.710.840.770.921.231.57
Other Funds (Non Cash)-0.953.083.981.480.070.34
Funds from Operations-23.13-30.12-18.56-24.39-25.47-8.14
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.423.08-15.4813.6528.75-14.69
Income Taxes Payable--0.980.54---
Cash from Operating Activities-24.55-27.04-34.04-10.753.28-22.83
Capital Expenditures-0.10-0.10-0.07-0.12-0.31-2.21
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.16
Purchase or Sale of Investments2.470.407.809.071.3124.63
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments2.470.407.809.071.3124.63
Other Uses0.000.12-0.120.000.000.00
Other Sources0.000.010.000.000.000.00
Cash from Investing Activities2.370.437.628.951.0122.58
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.001.1616.313.070.100.05
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.001.1616.313.070.100.05
Proceedsfrom Stock Options0.001.1616.313.070.100.05
Issuance or Reduction of Debt, Net-2.76-5.53-4.87-4.90-4.78-0.83
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-2.76-4.3611.44-1.83-4.68-0.78
Exchange Rate Effect-0.300.161.12-0.27-0.280.14
Net Change in Cash-25.23-30.81-13.86-3.89-0.67-0.89
Free Cash Flow-24.65-27.14-34.10-10.862.98-22.88

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 21.77M 2025: 10.16M
France2024: 21.77M 2025: 10.16M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-30-0.1M-157.28K
2026-10-15-0.1M-155.86K
2026-09-30-0.1M-151.09K
2026-09-15-0.1M-142.57K
2026-08-31-0.1M-147.97K
2026-08-14-0.2M-151.35K
2026-07-31-0.2M-64.49K
2026-07-15-0.2M-69.53K
2026-06-30-0.2M-72.35K
2026-06-15-0.2M-73.86K
2026-05-29-0.2M-68.01K
2026-05-15-0.2M-64.18K
2026-04-30-0.1M-23.77K
2026-04-15-0.1M-23.09K
2026-03-31-0.1M-20.48K
2026-03-13-0.1M-22.67K
2026-02-27-0.1M-22.03K
2026-02-13-0.1M-23.97K
2026-01-30-0.2M-198.71K
2026-01-15-0.2M-197.00K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-05SEC
2026-10-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-27SEC
2026-10-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-21SEC
2026-10-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-20SEC
2026-09-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-17SEC
2026-09-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-16SEC
2026-09-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-09-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-10SEC
2026-09-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-02SEC
2026-08-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-19SEC
2026-08-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-14SEC
2026-08-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-10SEC
2026-07-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-23SEC
2026-07-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-21SEC
2026-06-22SCHEDULE 13G/ASEC
2026-05-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-22SEC
2026-05-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-19SEC
2026-05-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-13SEC
2026-05-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-12SEC
2026-05-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-06SEC
2026-04-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-23SEC
2026-04-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-17SEC
2026-04-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-13SEC
2026-04-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-13SEC
2026-04-10SCHEDULE 13G/ASEC
2026-04-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-08SEC
2026-04-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-03SEC
2026-04-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-02SEC
2026-04-0120-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-03-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-26SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Lion Point Capital, LP0.09%
MORGAN STANLEY0.05%
SmartHarvest Portfolios, LLC0.02%
XTX Topco Ltd0.02%
CITADEL ADVISORS LLC0.01%
JANE STREET GROUP, LLC0.01%
RHUMBLINE ADVISERS0.00%
UBS Group AG0.00%
Caitong International Asset Management Co., Ltd0.00%
Farther Finance Advisors, LLC0.00%

Funds

Fund% owned
-

OakChart. IPHA. Cached 15 minutes.

Some panels did not load: insider.